Budget impact analysis shows MP-AzeFlu offers cost-neutral effects for allergic rhinitis, suggesting potential savings with therapy changes.
The introduction of MP-AzeFlu in Saudi Arabia and the United Arab Emirates showed cost-neutral to cost-saving impacts, depending on whether it replaces dual or triple therapy regimens.
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Current Medical Research and Opinion